Form 4: ImmunityBio Director Sells Shares After Option Exercise
Insider Transaction Report
ImmunityBio Director Christobel Selecky exercised stock options and subsequently sold shares in January 2026, pursuant to a pre-arranged 10b5-1 trading plan.
Summary
- Director Christobel Selecky exercised stock options to acquire 50,000 shares of ImmunityBio Common Stock at an exercise price of $2.98 per share on January 16, 2026.
- On the same day, January 16, 2026, Selecky sold all 50,000 shares of Common Stock at a price of $5.00 per share.
- Selecky further exercised stock options to acquire 25,000 shares of ImmunityBio Common Stock at an exercise price of $2.98 per share on January 20, 2026.
- On January 20, 2026, Selecky sold all 25,000 shares of Common Stock at a weighted average price of $7.506 per share, with sales occurring in the price range of $7.50 to $7.52.
- All reported sales were executed under a Rule 10b5-1 trading plan adopted by Selecky on June 12, 2025.
- The stock options exercised had fully vested on June 12, 2023, the day before the 2023 annual meeting of stockholders.
- Following these transactions, Selecky's direct beneficial ownership of ImmunityBio Common Stock is 0 shares, and beneficial ownership of stock options is 92,937.
Sentiment
Score: 6
Explanation: The filing reports routine insider transactions (option exercise and sale) executed under a pre-arranged trading plan, indicating a director realizing compensation. The sales occurred at prices significantly above the exercise price, which is positive for the director, but the filing itself is neutral regarding the company's operational performance or future prospects.
Positives
- Director Selecky realized a significant profit by exercising options at $2.98 and selling shares at $5.00 and a weighted average of $7.506, indicating a favorable market price relative to the option strike price.
Negatives
- Director's direct beneficial ownership of common stock decreased to 0 following the reported sales, reducing direct insider alignment with common shareholders.
Future Outlook
NA
Management Comments
- The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.
- The weighted average share price of an aggregate total of 25,000 shares sold in the price range of $7.50 to $7.52 by the Reporting Person.
- One hundred percent (100%) of the shares subject to the award vested on June 12, 2023, the date immediately preceding the 2023 annual meeting of stockholders.
Industry Context
This Form 4 filing reports routine insider transactions and does not provide information related to broader industry trends or competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization of Attorney-in-Fact | Christobel Selecky granted a Power of Attorney to several individuals (Richard Adcock, David C. Sachs, Regan J. Lauer, Philip LoScalzo, Benjamin J. Capps, and Brandon Shaw) to prepare, execute, and submit SEC reports (including Forms 3, 4, 5, Schedules 13D, 13G, and Forms 144) on her behalf. | October 30, 2025 | This streamlines compliance with SEC reporting requirements for the reporting person, ensuring timely and accurate filings for beneficial ownership changes. |
Stakeholder Impact
- Shareholders: Provides transparency regarding insider trading activity, showing a director monetizing vested options. The sales at prices significantly higher than the exercise price could be viewed as a positive indicator of stock value, but also represent a reduction in the director's direct equity holdings.
Key Dates
| Date | Description |
|---|---|
| 06/12/2023 | Date 100% of the shares subject to the stock option award vested. |
| 06/12/2025 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 10/30/2025 | Date the Power of Attorney was executed by Christobel Selecky. |
| 01/16/2026 | Transaction date for the exercise of 50,000 stock options and subsequent sale of 50,000 common shares. |
| 01/20/2026 | Transaction date for the exercise of 25,000 stock options and subsequent sale of 25,000 common shares. |
| 01/21/2026 | Date the Form 4 was signed and filed. |
Recommendation
holdThis Form 4 details routine insider transactions (option exercise and subsequent sale) executed under a pre-arranged 10b5-1 trading plan. While the director realized a profit, these transactions do not provide new fundamental information about ImmunityBio's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.
Keywords
ImmunityBio, IBRX, Form 4, Insider Transaction, Stock Options, Director, Share Sale, 10b5-1 Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.